Absorb生物可吸收支架治疗冠状动脉疾病的2年结局:七项随机试验的系统综述与荟萃分析及个体患者数据子研究
该系统综述与荟萃分析纳入七项随机试验共5583例患者,比较Absorb生物可吸收血管支架(BVS)与金属依维莫司洗脱支架(EES)的2年结局。BVS组2年器械导向复合终点风险高于EES组(9.4% vs 7.4%,RR 1.29,95%CI 1.08-1.56,p=0.0059),主要由靶血管相关心肌梗死和缺血驱动的靶病变血运重建增加驱动,器械血栓累积发生率亦更高(2.3% vs 0.7%,RR 3.35,95%CI 1.96-5.72,p<0.0001)。1至2年 landmark 分析同样显示BVS组器械导向复合终点和器械血栓发生率更高。
要点
- BVS组2年器械导向复合终点风险高于EES组(9.4% vs 7.4%,RR 1.29,95%CI 1.08-1.56,p=0.0059)。
- BVS组2年器械血栓累积发生率高于EES组(2.3% vs 0.7%,RR 3.35,95%CI 1.96-5.72,p<0.0001)。
- 1至2年 landmark 分析中BVS组器械导向复合终点(3.3% vs 1.9%,RR 1.64,95%CI 1.03-2.61,p=0.0376)和器械血栓(0.5% vs 0%,p<0.0001)发生率均更高。
核心结论
- 与EES相比,BVS在2年累积及1至2年随访期间均与器械导向复合不良事件和器械血栓发生率增加相关。
研究设计与样本
- 系统综述与荟萃分析,纳入七项随机试验,共5583例患者随机分配至Absorb BVS(n=3261)或金属EES(n=2322),随访至少2年。
- 检索MEDLINE、Cochrane数据库、TCTMD、ClinicalTrials.gov、Clinical Trial Results、CardioSource及主要心血管会议摘要和报告,截至2017年4月1日。
- 主要疗效终点为器械导向复合终点(心源性死亡、靶血管相关心肌梗死或缺血驱动的靶病变血运重建),主要安全终点为明确的或可能的器械血栓。
- 利用四项ABSORB试验的个体患者数据进行landmark分析、亚组分析和多变量建模。
主要发现
- BVS组2年器械导向复合终点风险高于EES组(9.4% [304/3217] vs 7.4% [169/2299];RR 1.29,95%CI 1.08-1.56,p=0.0059)。
- BVS组靶血管相关心肌梗死发生率高于EES组(5.8% [187/3218] vs 3.2% [74/2299];RR 1.68,95%CI 1.29-2.19,p=0.0003)。
- BVS组缺血驱动的靶病变血运重建发生率高于EES组(5.3% [169/3217] vs 3.9% [90/2300];RR 1.40,95%CI 1.09-1.80,p=0.0090)。
- BVS组与EES组心源性死亡差异无统计学意义。
- BVS组2年器械血栓累积发生率高于EES组(2.3% [73/3187] vs 0.7% [16/2281];RR 3.35,95%CI 1.96-5.72,p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term outcomes of percutaneous coronary intervention after their complete bioresorption. Randomised trials have shown non-inferiority between BVS and metallic drug-eluting stents at 1 year in composite safety and effectiveness outcomes, although some increases in rates of target vessel-related myocardial infarction and device thrombosis were identified. Outcomes of BVS following the first year after implantation are unknown. We sought to ascertain whether BVS are as safe and effective as drug-eluting stents within 2 years after implantation and between 1 and 2 years. METHODS: We did a systematic review and meta-analysis of randomised trials in which patients were randomly assigned to everolimus-eluting Absorb BVS or metallic everolimus-eluting stents (EES) and followed up for at least 2 years. We searched MEDLINE, the Cochrane database, TCTMD, ClinicalTrials.gov, Clinical Trial Results, CardioSource, and abstracts and presentations from major cardiovascular meetings up to April 1, 2017, to identify relevant studies. The primary efficacy outcome measure was the device-oriented composite endpoint (cardiac mortality, target vessel-related myocardial infarction, or ischaemia-driven target lesion revascularisation) and the primary safety outcome measure was definite or probable device thrombosis. Individual patient data from the four ABSORB trials were used for landmark and subgroup analysis and multivariable modelling. FINDINGS: We identified seven randomised trials in which 5583 patients were randomly assigned to Absorb BVS (n=3261) or metallic EES (n=2322) and followed up for 2 years. BVS had higher 2-year relative risks of the device-oriented composite endpoint than did EES (9·4% [304 of 3217] vs 7·4% [169 of 2299]; relative risk [RR] 1·29 [95% CI 1·08-1·56], p=0·0059). These differences were driven by increased rates of target vessel-related myocardial infarction (5·8% [187 of 3218] vs 3·2% [74 of 2299]; RR 1·68 [95% CI 1·29-2·19], p=0·0003) and ischaemia-driven target lesion revascularisation (5·3% [169 of 3217] vs 3·9% [90 of 2300]; 1·40 [1·09-1·80], p=0·0090) with BVS, with non-significant differences in cardiac mortality. The cumulative 2-year incidence of device thrombosis was higher with BVS than with EES (2·3% [73 of 3187] vs 0·7% [16 of 2281]; RR 3·35 [95% CI 1·96-5·72], p<0·0001). Landmark analysis between 1 and 2 years also showed higher rates of the device-oriented composite endpoint (3·3% [69 of 2100] vs 1·9% [23 of 1193]; RR 1·64 [95% CI 1·03-2·61], p=0·0376) and device thrombosis (0·5% [11 of 2085] vs none [0 of 1183], p<0·0001) in BVS-treated patients than in EES-treated patients. INTERPRETATION: BVS was associated with increased rates of composite device-oriented adverse events and device thrombosis cumulatively at 2 years and between 1 and 2 years of follow-up compared with EES. FUNDING: Abbott Vascular.
引用
- Ali ZA, Serruys PW, Kimura T, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet. 2017. PMID: 28732815. doi:10.1016/S0140-6736(17)31470-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。